Qube Research & Technologies LTD Alaunos Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.04 - $0.13 $7 - $23	-179 Reduced 10.14%	1,587 $0
Q3 2023 Nov 13, 2023	BUY	$0.12 - $0.5 $211 - $883	1,766 New	1,766 $0
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $49,025 - $25.6 Million	-98,050 Reduced 64.78%	53,320 $34,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $7,638 - $2.37 Million	7,345 Added 5.1%	151,370 $260,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $1.24 $59,050 - $178,591	144,025 New	144,025 $179,000
Q1 2022 May 09, 2022	SELL	$0.62 - $1.17 $235,454 - $444,326	-379,766 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$1.09 - $1.89 $413,944 - $717,757	379,766 New	379,766 $414,000
Q3 2021 Nov 12, 2021	SELL	$1.44 - $2.73 $69,262 - $131,310	-48,099 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.63 - $3.67 $126,500 - $176,523	48,099 New	48,099 $127,000
Q1 2021 May 14, 2021	SELL	$2.82 - $5.6 $110,377 - $219,189	-39,141 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.09 - $3.09 $81,804 - $120,945	39,141 New	39,141 $99,000
Q2 2020 Aug 14, 2020	SELL	$2.2 - $3.71 $64,873 - $109,400	-29,488 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.9 - $4.98 $56,027 - $146,850	29,488 New	29,488 $72,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.